Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

C

Chong Kun Dang

Status and phase

Unknown
Phase 3

Conditions

Type2 Diabetes

Treatments

Drug: CKD-501 0.5mg
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03627182
19DM17015

Details and patient eligibility

About

The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.

Full description

The aim of this phase III study was to evaluate the efficacy and safety of additional combined CKD-501 administration for 24 weeks in patients with type 2 diabetes who were not adequately controlled for blood glucose by the combination of D150 and D745 25mg . Furthermore, the extension study for additional 28 weeks is designed to confirm long term safety of actual drug as an oral hypoglycemic agent.

Enrollment

240 estimated patients

Sex

All

Ages

19 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Between 19 years and 75 years old(male or female)
  • Type Ⅱ diabetes mellitus
  • The patient who has been taking oral hypoglycemic agent at least 8weeks with HbA1c 7 to 10% at screening test
  • Body Mass Index between 21kg/㎡ and 40kg/㎡
  • C-peptide > 1.0 ng/ml
  • Agreement with written informed consent
  • HbA1c 7 to 10% after Run-in period

Exclusion criteria

  • Type I diabetes or secondary diabetes
  • Continuous or non continuous treatment(over 7 days) insulin within 3 months prior to screening
  • Treatment with Thiazolidinedione within 3months or patient who has experience such as hypersensitivity reaction, serious adverse event with Thiazolidinedione(TZD), sodium glucose cotransporter 2(SGLT2) inhibitor, Biguanide.
  • Chronic(continuous over 7 days) oral or non oral corticosteroids treatment within 1 month prior to screening
  • Treatment with anti-obesity drugs within 3months
  • Past history: lactic acidosis, genetic problem such as galactose intolerance, etc.
  • Acute or chronic metabolic acidosis including diabetic ketoacidosis
  • History of proliferative diabetic retinopathy
  • Patient with severe infection, severe injury
  • Patients with urinary tract infection including urinary tract sepsis and pyelonephritis
  • Malnutrition, weakness, starvation, hyposthenia, pituitary insufficiency or adrenal insufficiency
  • History of malignant tumor within 5years
  • Drug abuse or history of alcoholism
  • Severe pulmonary dysfunction
  • Severe GI disorder
  • History of myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage or unstable angina within 6 months
  • Abnormal lab result: ① Fasting Plasma Glucose > 270 mg/dl ② Triglyceride ≥ 500 mg/dl ③ Significant liver dysfunction or AST(Aspartate transaminase)/ALT(Alanine transaminase) ≥ normal range*3 or Total bilirubin ≥ normal range*2 ④ Hemoglobin<10.5g/dL ⑤ Abnormality of thyroid function(significantly out of normal TSH(Thyroid Stimulating Hormone) range)
  • eGFR(Estimated glomerular filtration rate) is less than 60ml/min/1.73m^2
  • Pregnant women or nursing mothers
  • Fertile women who not practice contraception with appropriate methods
  • Participated in other trial within 4 weeks or participating in other trial at present
  • In investigator's judgment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

240 participants in 2 patient groups, including a placebo group

CKD-501 0.5mg
Experimental group
Description:
CKD-501 0.5mg
Treatment:
Drug: CKD-501 0.5mg
Placebo
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

BongSoo Cha, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems